National Treasure Investment Firm Redhill to Present Oral COVID-19 Treatment at Conference

[Asia Economy Reporter Jang Hyowon] RedHill Biopharma, a US/Israel biotechnology company in which Kospi-listed Kukbo Co., Ltd. has acquired shares, announced in a press release on the 12th (local US time) that it will disclose data on Talicia®’s Helicobacter pylori (H.pylori) eradication therapy, the oral COVID-19 treatments Opaganib and RHB-107 (upamostat), and the progress of late-stage clinical trials and COVID-19 programs at the ‘Scientific Conference’ to be held in July and August this year.

In this announcement, RedHill stated that it will reveal excellent efficacy and safety data on the new oral COVID-19 treatments Opaganib and RHB-107, which are designed to counter virus variants, at the International Conference on Emerging Infectious Diseases (ICEID), the top infectious disease forum hosted by the US Centers for Disease Control and Prevention (CDC) and the Global Task Force for Health.

Prior to this, at the 2nd ARDS Drug Development Summit held until the 15th, RedHill will disclose data related to Opaganib and propose a new disease severity classification paradigm for COVID-19 using the baseline of Fraction of Inspired Oxygen (FiO2) as a criterion. The phase 2/3 data will show that the mortality rate of treated patients with FiO2 at 60% decreased by up to 62%.

Additionally, RedHill announced that it has sent invitations to relevant researchers to present important clinical results, including high eradication rates across body mass index (BMI) groups for Talicia, the leading US brand for H.pylori eradication therapy, at the World Gastro 2022 Congress.

Meanwhile, Kukbo acquired shares of RedHill Biopharma on November 8 last year and was granted the first negotiation rights for distribution contracts covering the domestic and major Asian markets for RedHill’s oral COVID-19 treatments Opaganib, RHB-107, and Talicia. Furthermore, Kukbo has signed an official license agreement granting exclusive commercialization rights for the moderate to severe oral COVID-19 treatment Opaganib within the Republic of Korea.

This content was produced with the assistance of AI translation services.